Massachusetts-based microbiome therapeutic company adds Arizona clinical space to their market mix. Seres Therapeutics’ BSL-3 20,000 SF Tempe clinic is centered around the patient experience with a highly specialized cleanroom and laboratory space to support the treatment and diagnosis of diseases relating to the human microbiome. The team did a building evaluation on two site locations to aid in the final decision, partnering with the design team to identify systems, equipment, and begin early procurement.
Operations for Seres Therapeutics are expected to begin in the first quarter of 2022. Located on the second level of a retail center in the thick of the Arizona State University campus, the facility hopes to provide easy access to clients and patients for diagnosis and research of their microbiome challenges. The company continues to grow at an astounding rate with further backing behind their clinical research. “Selecting Arizona as a destination for their first out of region location is exciting and they are definitely on the forefront of biotechnology,” Biotechnology Market Leader Gonzo Gonzalez said. “They have been a great partner with a steadfast commitment to the patient throughout design and construction.”